Target Name: UBE2NL
NCBI ID: G389898
Other Name(s): UBE2NL variant coding | Ubiquitin-conjugating enzyme E2N-like | UE2NL_HUMAN | ubiquitin conjugating enzyme E2 N like (gene/pseudogene) | Putative ubiquitin-conjugating enzyme E2 N-like | Ubiquitin conjugating enzyme E2 N like (gene/pseudogene), transcript variant coding | Li174 | epididymis tissue protein Li 174 | Epididymis tissue protein Li 174 | ubiquitin conjugating enzyme E2N-like

Understanding The Potential Role of UBE2NL as A Drug Target Or Biomarker

UBE2NL, also known as UBE2NL variant coding, is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. UBE2NL is a non-coding RNA molecule that has been shown to play a role in the regulation of gene expression and has been linked to the development and progression of various diseases.

The UBE2NL gene is located on chromosome 6p21 and has been shown to encode for a protein that is involved in the regulation of gene expression and has been implicated in the development and progression of various diseases. UBE2NL has been shown to play a role in the regulation of stem cell proliferation and has been linked to the development of cancer.

Studies have also shown that UBE2NL is involved in the regulation of neural cell survival and has been implicated in the development and progression of neurodegenerative diseases. UBE2NL has been shown to play a role in the regulation of dendrites formation in neurons and has been linked to the development of neurodegenerative diseases.

In addition to its role in the regulation of neural cell survival, UBE2NL has also been shown to play a role in the regulation of immune cell function. UBE2NL has been shown to be involved in the regulation of T cell development and has been linked to the development of autoimmune disorders.

Despite the potential implications of UBE2NL as a drug target or biomarker, more research is needed to fully understand its role in the development and progression of various diseases. Further studies are needed to determine the exact mechanism of action of UBE2NL and to explore its potential as a drug or biomarker.

In conclusion, UBE2NL is a gene that has been identified as a potential drug target or biomarker for various diseases. Further research is needed to fully understand its role in the development and progression of these diseases and to explore its potential as a drug or biomarker.

Protein Name: Ubiquitin Conjugating Enzyme E2 N Like (gene/pseudogene)

More Common Targets

UBE2O | UBE2Q1 | UBE2Q2 | UBE2Q2P1 | UBE2Q2P11 | UBE2Q2P13 | UBE2Q2P16 | UBE2Q2P2 | UBE2QL1 | UBE2R2 | UBE2R2-AS1 | UBE2S | UBE2T | UBE2U | UBE2V1 | UBE2V1P2 | UBE2V1P9 | UBE2V2 | UBE2V2P1 | UBE2W | UBE2Z | UBE3A | UBE3B | UBE3C | UBE3D | UBE4A | UBE4B | UBFD1 | UBIAD1 | Ubiquitin carboxyl-terminal hydrolase 17-like protein 24 | Ubiquitin E3 ligase (ASB2, TCEB1, TCEB2, CUL5, RNF7) complex | UBL3 | UBL4A | UBL4B | UBL5 | UBL5P3 | UBL7 | UBL7-DT | UBLCP1 | UBN1 | UBN2 | UBOX5 | UBOX5-AS1 | UBP1 | UBQLN1 | UBQLN1-AS1 | UBQLN2 | UBQLN3 | UBQLN4 | UBQLNL | UBR1 | UBR2 | UBR3 | UBR4 | UBR5 | UBR5-DT | UBR7 | UBTD1 | UBTD2 | UBTF | UBTFL1 | UBTFL2 | UBTFL6 | UBXN1 | UBXN10 | UBXN11 | UBXN2A | UBXN2B | UBXN4 | UBXN6 | UBXN7 | UBXN8 | UCA1 | UCHL1 | UCHL1-DT | UCHL3 | UCHL5 | UCK1 | UCK2 | UCKL1 | UCKL1-AS1 | UCMA | UCN | UCN2 | UCN3 | UCP1 | UCP2 | UCP3 | UDP-Glycosyltransferase | UDP-N-Acetylglucosamine--Peptide N-Acetylglucosaminyltransferase (O-GlcNAc Transferase) | UEVLD | UFC1 | UFD1 | UFD1-AS1 | UFL1 | UFM1 | UFSP1 | UFSP2 | UGCG | UGDH